{"title":"Immunochemotherapy in patients with non-squamous lung cancer","authors":"A. Płużański, A. Piórek","doi":"10.5603/ocp.97614","DOIUrl":"https://doi.org/10.5603/ocp.97614","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":" 27","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138964414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chemotherapy in patients with testicular germ-cell tumors and end-stage renal disease requiring hemodialysis: two case reports","authors":"Martyna Tyszka, Letycja Róg, Jolanta Małyszko, Rafał Stec","doi":"10.5603/ocp.96750","DOIUrl":"https://doi.org/10.5603/ocp.96750","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"31 2","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139010288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ireneusz Raczyński, Agnieszka Siedlaczek, Joanna Streb, Patryk Zając, B. Czartoryska-Arłukowicz, Aleksandra Chruściana-Bołtuć, Małgorzata Talerczyk, Katarzyna Wierzbicka, Weronika Radecka, Michał Jurczyk, Barbara Radecka
{"title":"Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index as clinical predictive and prognostic markers in patients with advanced pancreatic cancer receiving gemcitabine monotherapy","authors":"Ireneusz Raczyński, Agnieszka Siedlaczek, Joanna Streb, Patryk Zając, B. Czartoryska-Arłukowicz, Aleksandra Chruściana-Bołtuć, Małgorzata Talerczyk, Katarzyna Wierzbicka, Weronika Radecka, Michał Jurczyk, Barbara Radecka","doi":"10.5603/ocp.98125","DOIUrl":"https://doi.org/10.5603/ocp.98125","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"18 23","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138984530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karolina P. Nalewaj, Izabela Chmielewska, P. Krawczyk, A. Grenda, Luiza Grzycka-Kowalik, I. Paśnik, Janusz Milanowski
{"title":"Tumor heterogeneity and its impact on sotorasib response in a patient with non-small cell lung cancer","authors":"Karolina P. Nalewaj, Izabela Chmielewska, P. Krawczyk, A. Grenda, Luiza Grzycka-Kowalik, I. Paśnik, Janusz Milanowski","doi":"10.5603/ocp.97722","DOIUrl":"https://doi.org/10.5603/ocp.97722","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"128 ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138985352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Systemic treatment in triple-negative breast cancer patients — standard and novel approaches","authors":"S. Dębska-Szmich, Piotr Potemski","doi":"10.5603/ocp.96485","DOIUrl":"https://doi.org/10.5603/ocp.96485","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"34 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138985167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A case of a patient with embryonal sarcoma presenting with abdominal pain","authors":"Mohsen Reza Mansoorian, Shahriar Sabouri","doi":"10.5603/ocp.95596","DOIUrl":"https://doi.org/10.5603/ocp.95596","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"44 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139201006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria Wysocka, A. Kieszkowska-Grudny, J. Klimkiewicz, Jerzy Jarosz, Martyna Hordowicz, Andrzej Silczuk, Tomasz Pasierski, A. Klimkiewicz
{"title":"Between “opioidophobia” and the opioid crisis: a cross-sectional comparison of opinions on opioid analgesic treatment between palliative care patients with cancer and physicians in Poland","authors":"Maria Wysocka, A. Kieszkowska-Grudny, J. Klimkiewicz, Jerzy Jarosz, Martyna Hordowicz, Andrzej Silczuk, Tomasz Pasierski, A. Klimkiewicz","doi":"10.5603/ocp.96515","DOIUrl":"https://doi.org/10.5603/ocp.96515","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"1029 ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139241135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Irene Solana López, D. Gutiérrez Abad, M. V. de Torres Olombrada, Elia Martínez Moreno, I. Juez Martel, Alicia Hurtado Nuño, Ana Manuela Martín Fernández de Soignie, C. De Zea Luque, Nadia Sánchez Baños, Fátima Escalona Martín, Beatriz Losada Vila, Carmen Pantín González, L. Rodríguez Lajusticia, Diego Malón Giménez, B. Jiménez Munarriz, Roberto Hernández López, J. Calzas Rodríguez, Juan Antonio Guerra Martínez
{"title":"Two-center experience comparing the use of the FLOT4 and CROSS schemes for patients with gastric, esophageal, and gastroesophageal junction adenocarcinoma","authors":"Irene Solana López, D. Gutiérrez Abad, M. V. de Torres Olombrada, Elia Martínez Moreno, I. Juez Martel, Alicia Hurtado Nuño, Ana Manuela Martín Fernández de Soignie, C. De Zea Luque, Nadia Sánchez Baños, Fátima Escalona Martín, Beatriz Losada Vila, Carmen Pantín González, L. Rodríguez Lajusticia, Diego Malón Giménez, B. Jiménez Munarriz, Roberto Hernández López, J. Calzas Rodríguez, Juan Antonio Guerra Martínez","doi":"10.5603/ocp.97428","DOIUrl":"https://doi.org/10.5603/ocp.97428","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"1 7","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139276568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Bożyk, K. Wojas-Krawczyk, M. Nicoś, P. Krawczyk
{"title":"The effect of different concentrations of anti-PD-1 and anti-PD-L1 antibodies on the activity of immune system cells in patients with non-small cell lung cancer","authors":"A. Bożyk, K. Wojas-Krawczyk, M. Nicoś, P. Krawczyk","doi":"10.5603/ocp.96792","DOIUrl":"https://doi.org/10.5603/ocp.96792","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"32 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139288137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In 2020, approximately 18,000 women in Poland were diagnosed with breast cancer, and 6,000 of them died. In recent years, we have witnessed significant progress in the diagnosis and treatment of breast cancer patients. When detected early and treated appropriately, the prognosis is very good, and even some patients with distant metastases have experienced long-term survival. The most common biological subtype is hormone receptor-positive breast cancer, accounting for about 70% of diagnoses, showing expression of estrogen and progesterone receptors. Triple-negative breast cancer and HER2-positive breast cancer each make up approximately 15% of all cases. In the treatment of advanced HER2-positive breast cancer, a combination of docetaxel with pertuzumab and trastuzumab is used in the first line. In subsequent lines of treatment, options include trastuzumab deruxtecan (T-DXd), trastuzumab emtansine, lapatinib, tucatinib, margetuximab, and trastuzumab. Trastuzumab derukstekan is an immunoconjugate that, upon entering the cell, releases a cytostatic agent that destroys its genetic material and neighboring cells (the “bystander effect”). It significantly prolongs the time to disease progression and overall survival compared to standard treatments used in the second and subsequent lines of treatment. It represents an effective and valuable therapeutic option for patients with early-stage HER2- positive metastatic breast cancer.
{"title":"Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer","authors":"Joanna Kufel-Grabowska","doi":"10.5603/ocp.97612","DOIUrl":"https://doi.org/10.5603/ocp.97612","url":null,"abstract":"In 2020, approximately 18,000 women in Poland were diagnosed with breast cancer, and 6,000 of them died. In recent years, we have witnessed significant progress in the diagnosis and treatment of breast cancer patients. When detected early and treated appropriately, the prognosis is very good, and even some patients with distant metastases have experienced long-term survival. The most common biological subtype is hormone receptor-positive breast cancer, accounting for about 70% of diagnoses, showing expression of estrogen and progesterone receptors. Triple-negative breast cancer and HER2-positive breast cancer each make up approximately 15% of all cases. In the treatment of advanced HER2-positive breast cancer, a combination of docetaxel with pertuzumab and trastuzumab is used in the first line. In subsequent lines of treatment, options include trastuzumab deruxtecan (T-DXd), trastuzumab emtansine, lapatinib, tucatinib, margetuximab, and trastuzumab. Trastuzumab derukstekan is an immunoconjugate that, upon entering the cell, releases a cytostatic agent that destroys its genetic material and neighboring cells (the “bystander effect”). It significantly prolongs the time to disease progression and overall survival compared to standard treatments used in the second and subsequent lines of treatment. It represents an effective and valuable therapeutic option for patients with early-stage HER2- positive metastatic breast cancer.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136233914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：